Myovant Sciences Ltd (MYOV) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:MYOV - BMG637AM1024 - Common Stock
MYOV Key Statistics, Chart & Performance
The current stock price of MYOV is 26.98 USD. In the past month the price increased by 0.33%. In the past year, price increased by 125.4%.
MYOV Latest News, Press Relases and Analysis
MYOV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About MYOV
Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. The firm is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company develops Relugolix for the treatment of men with advanced prostate cancer. The firm is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
Company Info
Myovant Sciences Ltd
Ste 1 3rd Fl, 11/12 St. James's Square
London SW1Y 4LB GB
CEO: David Marek
Employees: 579
Phone: 442074003351.0
Myovant Sciences Ltd / MYOV FAQ
What does MYOV do?
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. The firm is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company develops Relugolix for the treatment of men with advanced prostate cancer. The firm is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
Can you provide the latest stock price for Myovant Sciences Ltd?
The current stock price of MYOV is 26.98 USD. The price decreased by -0.04% in the last trading session.
Does MYOV stock pay dividends?
MYOV does not pay a dividend.
What is the ChartMill technical and fundamental rating of MYOV stock?
MYOV has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is Myovant Sciences Ltd (MYOV) expected to grow?
The Revenue of Myovant Sciences Ltd (MYOV) is expected to grow by 81.1% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for Myovant Sciences Ltd?
Myovant Sciences Ltd (MYOV) has a market capitalization of 2.62B USD. This makes MYOV a Mid Cap stock.
MYOV Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MYOV. When comparing the yearly performance of all stocks, MYOV is one of the better performing stocks in the market, outperforming 98.07% of all stocks.
MYOV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYOV. Both the profitability and financial health of MYOV have multiple concerns.
MYOV Financial Highlights
Over the last trailing twelve months MYOV reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS increased by 22.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MYOV Forecast & Estimates
10 analysts have analysed MYOV and the average price target is 27.54 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 26.98.
For the next year, analysts expect an EPS growth of 19.42% and a revenue growth 81.1% for MYOV